Invention Grant
- Patent Title: Growth hormones with prolonged in-vivo efficacy
-
Application No.: US13522390Application Date: 2011-01-24
-
Publication No.: US09695226B2Publication Date: 2017-07-04
- Inventor: Carsten Behrens , Nils Langeland Johansen , Henrik Sune Andersen , Leif Noerskov-Lauritsen , Jens Buchardt
- Applicant: Carsten Behrens , Nils Langeland Johansen , Henrik Sune Andersen , Leif Noerskov-Lauritsen , Jens Buchardt
- Applicant Address: CH Zurich
- Assignee: Novo Nordisk HealthCare AG
- Current Assignee: Novo Nordisk HealthCare AG
- Current Assignee Address: CH Zurich
- Agent Jianjie Hu
- Priority: EP10151405 20100122
- International Application: PCT/EP2011/050923 WO 20110124
- International Announcement: WO2011/089255 WO 20110728
- Main IPC: A61K38/00
- IPC: A61K38/00 ; C07K14/61 ; A61K47/48
Abstract:
The invention relates to growth hormone compounds with a protracted profile. The effect is obtained by linking an albumin binding residue via a hydrophilic spacer to growth hormone variants. Further described are methods of preparing and using such compounds. These growth hormone compounds are based on there altered profile considered particular useful in therapy.
Public/Granted literature
- US20120309944A1 Growth Hormones With Prolonged In-Vivo Efficacy Public/Granted day:2012-12-06
Information query
IPC分类:
